In this study, using genetic and pharmacological models, we demonstrate that Ezh2 clearly has contrasting roles at different disease stages—a tumor-suppressive function during leukemogenesis and an oncogenic function during leukemia maintenance—the first such demonstration for an epigenetic regulator. This evidence concerns the gene EZH2 and leukemia.